{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T02:22:00Z","timestamp":1789525320871,"version":"build-2803163510"},"reference-count":37,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,4,7]],"date-time":"2026-04-07T00:00:00Z","timestamp":1775520000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Osteoporosis and bone density reduction are significant health concerns in elderly populations. While aging is a primary factor, drug-induced bone loss\u2014particularly associated with antiviral agents, proton pump inhibitors (PPIs), and immunomodulatory drugs\u2014has become a growing issue in patients managing multiple conditions.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>This study aims to comprehensively assess adverse drug reactions (ADRs) related to bone density reduction and osteoporosis in elderly patients using the FDA Adverse Event Reporting System (FAERS). A specific focus is placed on HIV patients using antiretroviral therapy (ART), alongside an exploration of gender differences and toxicological mechanisms of high-risk drugs.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Data from FAERS (2004-Q2 2025) were analyzed using disproportionality analysis (DPA) to calculate Reporting Odds Ratios (RORs) and 95% confidence intervals (CIs). Toxicological analysis was conducted on high-risk drugs (e.g., Tenofovir Disoproxil) using PubChem, GeneCards, and GO\/KEGG pathway enrichment to identify disrupted biological processes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Antiretroviral drugs exhibited the most significant risk signals. For decreased bone density, Emtricitabine\/Tenofovir Disoproxil (ROR = 713.48, 95% CI: 648.66\u2013784.79) and Tenofovir Disoproxil (ROR = 665.79, 95% CI: 611.91\u2013724.42) showed extreme associations. For osteoporosis, significant signals were also identified for these antivirals, as well as for Esomeprazole (ROR = 12.23, 95% CI: 11.27\u201313.28) and Adalimumab (ROR = 2.16, 95% CI: 1.99\u20132.35). Gender-specific differences indicated men are at higher risk from antiviral drugs, whereas women are more affected by bone metabolic and immunomodulatory regulators. Toxicological analyses suggest these drugs disrupt vitamin D metabolism, calcium homeostasis, and parathyroid hormone (PTH) signaling.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Long-term use of antiretroviral drugs, PPIs, and immunomodulators is strongly linked to bone metabolic disorders in the elderly. Although pharmacovigilance studies utilizing FAERS are limited by spontaneous reporting bias and the inability to establish direct causality, these quantitative findings and toxicological insights provide robust real-world evidence for enhancing clinical monitoring and personalized risk management.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fphar.2026.1790867","type":"journal-article","created":{"date-parts":[[2026,4,7]],"date-time":"2026-04-07T05:28:31Z","timestamp":1775539711000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Real-world pharmacovigilance of drug-induced osteoporosis: a focus on antiretroviral therapy and toxicological mechanisms in the elderly"],"prefix":"10.3389","volume":"17","author":[{"given":"Xiaoyu","family":"Liu","sequence":"first","affiliation":[{"name":"Clinical College of Chinese Medicine, Gansu University of Chinese Medicine","place":["Lanzhou, Gansu, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanlong","family":"Gong","sequence":"additional","affiliation":[{"name":"Minimally Invasive Spine Orthopedics, Affiliated Hospital of Gansu University of Chinese Medicine","place":["Lanzhou, Gansu, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lu","family":"Liu","sequence":"additional","affiliation":[{"name":"Clinical College of Chinese Medicine, Gansu University of Chinese Medicine","place":["Lanzhou, Gansu, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaomin","family":"Wang","sequence":"additional","affiliation":[{"name":"Clinical College of Chinese Medicine, Gansu University of Chinese Medicine","place":["Lanzhou, Gansu, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kangyi","family":"Hu","sequence":"additional","affiliation":[{"name":"Clinical College of Chinese Medicine, Gansu University of Chinese Medicine","place":["Lanzhou, Gansu, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min","family":"Song","sequence":"additional","affiliation":[{"name":"Clinical College of Chinese Medicine, Gansu University of Chinese Medicine","place":["Lanzhou, Gansu, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongjia","family":"Song","sequence":"additional","affiliation":[{"name":"Clinical College of Chinese Medicine, Gansu University of Chinese Medicine","place":["Lanzhou, Gansu, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,4,7]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"573","DOI":"10.18553\/jmcp.2019.25.5.573","article-title":"Associations between chronic disease, polypharmacy, and medication-related problems among medicare beneficiaries","volume":"25","author":"Almodovar","year":"2019","journal-title":"J. Manag. Care Spec. Pharm."},{"key":"B2","doi-asserted-by":"publisher","first-page":"624","DOI":"10.1007\/s00223-022-00946-4","article-title":"Osteoporosis and HIV infection","volume":"110","author":"Biver","year":"2022","journal-title":"Calcif. Tissue Int."},{"key":"B3","doi-asserted-by":"publisher","first-page":"197","DOI":"10.2165\/00063030-200923030-00006","article-title":"Spotlight on teriparatide in osteoporosis","volume":"23","author":"Blick","year":"2009","journal-title":"BioDrugs"},{"key":"B4","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1038\/s41584-024-01120-w","article-title":"Osteoporosis and fracture risk are multifactorial in patients with inflammatory rheumatic diseases","volume":"20","author":"Buttgereit","year":"2024","journal-title":"Nat. Rev. Rheumatol."},{"key":"B5","doi-asserted-by":"publisher","first-page":"547","DOI":"10.15252\/emmm.201404487","article-title":"Low-dose TNF augments fracture healing in normal and osteoporotic bone by up-regulating the innate immune response","volume":"7","author":"Chan","year":"2015","journal-title":"EMBO Mol. Med."},{"key":"B6","doi-asserted-by":"publisher","first-page":"1376","DOI":"10.3390\/ijms23031376","article-title":"Osteoporosis due to hormone imbalance: an overview of the effects of estrogen deficiency and glucocorticoid overuse on bone turnover","volume":"23","author":"Cheng","year":"2022","journal-title":"Int. Journal Molecular Sciences"},{"key":"B7","doi-asserted-by":"publisher","first-page":"117050","DOI":"10.1016\/j.bone.2024.117050","article-title":"TNF-Alpha promotes osteocyte necroptosis by upregulating TLR4 in postmenopausal osteoporosis","volume":"182","author":"Cui","year":"2024","journal-title":"Bone"},{"key":"B8","doi-asserted-by":"publisher","first-page":"1752","DOI":"10.3390\/medicina59101752","article-title":"The RANK-RANKL-OPG System: a multifaceted regulator of homeostasis, immunity, and cancer","volume":"59","author":"De Leon-Oliva","year":"2023","journal-title":"Med. Kaunas. Lith."},{"key":"B9","doi-asserted-by":"publisher","first-page":"1582908","DOI":"10.3389\/fphar.2025.1582908","article-title":"Evaluating the risk of osteoporosis-related adverse events with proton pump inhibitors: a pharmacovigilance study","volume":"16","author":"Di","year":"2025","journal-title":"Front. Pharmacol."},{"key":"B10","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1517\/14740338.2014.860133","article-title":"Denosumab in osteoporosis","volume":"13","author":"Diab","year":"2014","journal-title":"Expert Opin. Drug Saf."},{"key":"B11","doi-asserted-by":"publisher","first-page":"2305","DOI":"10.3390\/biomedicines13092305","article-title":"Bone mineral density in HIV-Infected people-the experience of Craiova regional Center","volume":"13","author":"Dumitrescu","year":"2025","journal-title":"Biomedicines"},{"key":"B12","doi-asserted-by":"publisher","first-page":"1595","DOI":"10.1210\/jc.2019-00221","article-title":"Pharmacological management of osteoporosis in postmenopausal women: an Endocrine Society* Clinical Practice Guideline","volume":"104","author":"Eastell","year":"2019","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"B13","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1016\/j.maturitas.2016.10.015","article-title":"Osteoporosis in postmenopausal women living with HIV","volume":"95","author":"Finnerty","year":"2017","journal-title":"Maturitas"},{"key":"B14","doi-asserted-by":"publisher","first-page":"898","DOI":"10.1016\/s0140-6736(99)05463-x","article-title":"Low serum IGF-1 and occurrence of osteoporotic fractures in postmenopausal women","volume":"355","author":"Garnero","year":"2000","journal-title":"Lancet"},{"key":"B15","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1016\/j.pop.2025.01.008","article-title":"Bone health in women","volume":"52","author":"Gibbons","year":"2025","journal-title":"Prim. Care"},{"key":"B16","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1038\/s41413-024-00321-z","article-title":"beta-Receptor blocker enhances the anabolic effect of PTH after osteoporotic fracture","volume":"12","author":"Huang","year":"2024","journal-title":"Bone Res."},{"key":"B17","doi-asserted-by":"publisher","first-page":"e10517","DOI":"10.1002\/jbm4.10517","article-title":"Renal contributions to age-related changes in mineral metabolism","volume":"5","author":"Irsik","year":"2021","journal-title":"JBMR Plus"},{"key":"B18","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1007\/s11892-019-1170-1","article-title":"Developmental programming of body composition: update on evidence and mechanisms","volume":"19","author":"Isganaitis","year":"2019","journal-title":"Curr. Diab Rep."},{"key":"B19","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1136\/annrheumdis-2011-200184","article-title":"Patients non-responding to etanercept obtain lower etanercept concentrations compared with responding patients","volume":"71","author":"Jamnitski","year":"2012","journal-title":"Ann. Rheum. Dis."},{"key":"B20","doi-asserted-by":"publisher","first-page":"e003779","DOI":"10.1136\/jitc-2021-003779","article-title":"Association of antibiotic treatment with immune-related adverse events in patients with cancer receiving immunotherapy","volume":"10","author":"Jing","year":"2022","journal-title":"J. Immunother. Cancer"},{"key":"B21","doi-asserted-by":"publisher","first-page":"1185","DOI":"10.1111\/apt.17716","article-title":"Tenofovir disoproxil fumarate versus tenofovir alafenamide on risk of osteoporotic fracture in patients with chronic hepatitis B: a nationwide claims study in South Korea","volume":"58","author":"Kim","year":"2023","journal-title":"Aliment. Pharmacol. Ther."},{"key":"B22","doi-asserted-by":"publisher","first-page":"1633","DOI":"10.1007\/s00198-024-07168-4","article-title":"Latent metabolic bone disease, skeletal dysplasia and other conditions related to low bone formation among 38 patients with subtrochanteric femoral fractures: a retrospective observational study","volume":"35","author":"Kimura","year":"2024","journal-title":"Osteoporos. Int."},{"key":"B23","doi-asserted-by":"publisher","first-page":"10733","DOI":"10.3390\/ijms231810733","article-title":"Proton pump inhibitors and bone health: an update narrative review","volume":"23","author":"Lespessailles","year":"2022","journal-title":"Int. J. Mol. Sci."},{"key":"B24","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1016\/j.ejphar.2017.09.015","article-title":"Macrolactin F inhibits RANKL-mediated osteoclastogenesis by suppressing Akt, MAPK and NFATc1 pathways and promotes osteoblastogenesis through a BMP-2\/smad\/Akt\/Runx2 signaling pathway","volume":"815","author":"Li","year":"2017","journal-title":"Eur. J. Pharmacol."},{"key":"B25","doi-asserted-by":"publisher","first-page":"1630412","DOI":"10.3389\/fpubh.2025.1630412","article-title":"Sex differences in drug-induced osteoporosis: a pharmacovigilance study based on the FAERS database","volume":"13","author":"Liu","year":"2025","journal-title":"Front. Public Health"},{"key":"B26","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1345\/aph.1R556","article-title":"Proton pump inhibitor-associated hypomagnesemia: what do FDA data tell us?","volume":"47","author":"Luk","year":"2013","journal-title":"Ann. Pharmacother."},{"key":"B27","doi-asserted-by":"publisher","first-page":"2007","DOI":"10.1002\/jbmr.3546","article-title":"Deletion of the Fanconi Anemia C gene in mice leads to skeletal anomalies and defective bone mineralization and microarchitecture","volume":"33","author":"Mazon","year":"2018","journal-title":"J. Bone Min. Res."},{"key":"B28","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1007\/s40620-016-0309-2","article-title":"PPIs and kidney disease: from AIN to CKD","volume":"29","author":"Moledina","year":"2016","journal-title":"J. Nephrol."},{"key":"B29","doi-asserted-by":"publisher","first-page":"115108","DOI":"10.1016\/j.intimp.2025.115108","article-title":"Different effects of tumor necrosis factor monoclonal antibody and receptor fusion protein on bone metabolism","volume":"162","author":"Ran","year":"2025","journal-title":"Int. Immunopharmacol."},{"key":"B30","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1007\/s00223-011-9499-8","article-title":"Adverse reactions and drug-drug interactions in the management of women with postmenopausal osteoporosis","volume":"89","author":"Rizzoli","year":"2011","journal-title":"Calcif. Tissue Int."},{"key":"B31","doi-asserted-by":"publisher","first-page":"2997","DOI":"10.1016\/S0140-6736(16)32389-3","article-title":"Fulvestrant 500 mg versus anastrozole 1 mg for hormone receptor-positive advanced breast cancer (FALCON): an international, randomised, double-blind, phase 3 trial","volume":"388","author":"Robertson","year":"2016","journal-title":"Lancet"},{"key":"B32","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1002\/pds.1001","article-title":"The reporting odds ratio and its advantages over the proportional reporting ratio","volume":"13","author":"Rothman","year":"2004","journal-title":"Pharmacoepidemiol Drug Saf."},{"key":"B33","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1186\/s13287-023-03271-1","article-title":"MiR-21-5p regulates the dynamic of mitochondria network and rejuvenates the senile phenotype of bone marrow stromal cells (BMSCs) isolated from osteoporotic SAM\/P6 mice","volume":"14","author":"Sikora","year":"2023","journal-title":"Stem Cell Res. Ther."},{"key":"B34","doi-asserted-by":"publisher","first-page":"1256","DOI":"10.3390\/life15081256","article-title":"Adverse events and drug interactions associated with Elexacaftor\/Tezacaftor\/Ivacaftor treatment: a descriptive Study across Australian, Canadian, and American adverse event databases","volume":"15","author":"Thiruchelvam","year":"2025","journal-title":"Life (Basel)"},{"key":"B35","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1007\/s00508-007-0844-x","article-title":"Prevalence and risk factors for osteopenia\/osteoporosis in an HIV-infected male population","volume":"119","author":"Tomazic","year":"2007","journal-title":"Wien Klin. Wochenschr"},{"key":"B36","doi-asserted-by":"publisher","first-page":"8120","DOI":"10.18632\/aging.103129","article-title":"Neuropeptide Y1 receptor antagonist promotes osteoporosis and microdamage repair and enhances osteogenic differentiation of bone marrow stem cells via cAMP\/PKA\/CREB pathway","volume":"12","author":"Xie","year":"2020","journal-title":"Aging (Albany NY)"},{"key":"B37","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1016\/j.jaip.2020.09.021","article-title":"Emerging causes of drug-induced anaphylaxis: a review of anaphylaxis-associated reports in the FDA Adverse Event Reporting System (FAERS)","volume":"9","author":"Yu","year":"2021","journal-title":"J. Allergy Clin. Immunol. Pract."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2026.1790867\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,7]],"date-time":"2026-04-07T05:28:33Z","timestamp":1775539713000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2026.1790867\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,7]]},"references-count":37,"alternative-id":["10.3389\/fphar.2026.1790867"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2026.1790867","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,7]]},"article-number":"1790867"}}